Anti-Jk3 in a Filipino man

Shaina McCaskill, Scott C Wise, Sheila Tinsley

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 62-year-old Filipino man with a history of chronic obstructive pulmonary disease, hypertension, and hyperlipidemia was admitted to the emergency department at Hospital A with recurrent fevers, weakness, and jaundice. The patient was evaluated and eventually discharged with a diagnosis of possible drug-induced hepatitis. One month later, the patient was admitted to Hospital B for recurrent fevers and weakness. The patient's hemoglobin was 3.8 g/dL. Six units of packed red blood cells (RBCs) were ordered for transfusion. The patient's sample typed as group B, D+, and the antibody screen was negative. All six units of packed RBCs appeared compatible (at immediate spin) and were transfused to the patient. His hemoglobin level 4 days post-transfusion was 9.3 g/dL, and the patient was discharged. The patient returned after a week for follow-up and his hemoglobin was found to have dropped to 8.5 g/dL, which continued to fall until it reached 7.0 g/dL. Additional packed RBCs were ordered for transfusion. During subsequent pre-transfusion compatibility testing, the antibody screen was found to be positive (all screening cells reactive at the antihuman globulin phase). An antibody identification panel was performed. The patient's serum was found to react with all panel cells tested, including the autocontrol tube. A direct antiglobulin test revealed the presence of both anti-IgG and anti-C3 coating the patient's RBCs. The specimen was then sent to a reference laboratory for further testing. Results from the reference lab testing revealed the presence of anti-Jk3 in the patient's serum. The patient was placed on steroids, and his reticulocyte count increased with no further signs of extravascular hemolysis. No additional transfusions were necessary. He was eventually discharged with a hemoglobin of 13.6 g/dL. The purpose of this case study is to report the findings of an extremely rare but clinically significant antibody, anti-Jk3.

Original languageEnglish (US)
Pages (from-to)119-122
Number of pages4
JournalImmunohematology
Volume31
Issue number2
StatePublished - Jan 1 2015

Fingerprint

Hemoglobins
Erythrocytes
Antibodies
Fever
Reticulocyte Count
Chemical and Drug Induced Liver Injury
Coombs Test
Globulins
Hemolysis
Jaundice
Hyperlipidemias
Serum
Pulmonary Hypertension
Chronic Obstructive Pulmonary Disease
Hospital Emergency Service
Anti-Idiotypic Antibodies
Steroids

Keywords

  • ABL1
  • AHG
  • Abelson murine leukemia viral oncogene homolog 1
  • Antihuman globulin
  • BCR
  • Breakpoint cluster region protein
  • DAT
  • DHTR
  • Delayed hemolytic transfusion reaction
  • Direct antiglobulin test
  • IVIG
  • Intravenous immunoglobulin
  • JAK2
  • Janus kinas 2 gene
  • MRCP
  • Magnetic resonance cholangiopancreatography

ASJC Scopus subject areas

  • Medicine(all)

Cite this

McCaskill, S., Wise, S. C., & Tinsley, S. (2015). Anti-Jk3 in a Filipino man. Immunohematology, 31(2), 119-122.

Anti-Jk3 in a Filipino man. / McCaskill, Shaina; Wise, Scott C; Tinsley, Sheila.

In: Immunohematology, Vol. 31, No. 2, 01.01.2015, p. 119-122.

Research output: Contribution to journalArticle

McCaskill, S, Wise, SC & Tinsley, S 2015, 'Anti-Jk3 in a Filipino man', Immunohematology, vol. 31, no. 2, pp. 119-122.
McCaskill S, Wise SC, Tinsley S. Anti-Jk3 in a Filipino man. Immunohematology. 2015 Jan 1;31(2):119-122.
McCaskill, Shaina ; Wise, Scott C ; Tinsley, Sheila. / Anti-Jk3 in a Filipino man. In: Immunohematology. 2015 ; Vol. 31, No. 2. pp. 119-122.
@article{32d5b8ec7fa9484fbef85e3e5f51e15a,
title = "Anti-Jk3 in a Filipino man",
abstract = "A 62-year-old Filipino man with a history of chronic obstructive pulmonary disease, hypertension, and hyperlipidemia was admitted to the emergency department at Hospital A with recurrent fevers, weakness, and jaundice. The patient was evaluated and eventually discharged with a diagnosis of possible drug-induced hepatitis. One month later, the patient was admitted to Hospital B for recurrent fevers and weakness. The patient's hemoglobin was 3.8 g/dL. Six units of packed red blood cells (RBCs) were ordered for transfusion. The patient's sample typed as group B, D+, and the antibody screen was negative. All six units of packed RBCs appeared compatible (at immediate spin) and were transfused to the patient. His hemoglobin level 4 days post-transfusion was 9.3 g/dL, and the patient was discharged. The patient returned after a week for follow-up and his hemoglobin was found to have dropped to 8.5 g/dL, which continued to fall until it reached 7.0 g/dL. Additional packed RBCs were ordered for transfusion. During subsequent pre-transfusion compatibility testing, the antibody screen was found to be positive (all screening cells reactive at the antihuman globulin phase). An antibody identification panel was performed. The patient's serum was found to react with all panel cells tested, including the autocontrol tube. A direct antiglobulin test revealed the presence of both anti-IgG and anti-C3 coating the patient's RBCs. The specimen was then sent to a reference laboratory for further testing. Results from the reference lab testing revealed the presence of anti-Jk3 in the patient's serum. The patient was placed on steroids, and his reticulocyte count increased with no further signs of extravascular hemolysis. No additional transfusions were necessary. He was eventually discharged with a hemoglobin of 13.6 g/dL. The purpose of this case study is to report the findings of an extremely rare but clinically significant antibody, anti-Jk3.",
keywords = "ABL1, AHG, Abelson murine leukemia viral oncogene homolog 1, Antihuman globulin, BCR, Breakpoint cluster region protein, DAT, DHTR, Delayed hemolytic transfusion reaction, Direct antiglobulin test, IVIG, Intravenous immunoglobulin, JAK2, Janus kinas 2 gene, MRCP, Magnetic resonance cholangiopancreatography",
author = "Shaina McCaskill and Wise, {Scott C} and Sheila Tinsley",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "31",
pages = "119--122",
journal = "Immunohematology / American Red Cross",
issn = "0894-203X",
publisher = "American Red Cross",
number = "2",

}

TY - JOUR

T1 - Anti-Jk3 in a Filipino man

AU - McCaskill, Shaina

AU - Wise, Scott C

AU - Tinsley, Sheila

PY - 2015/1/1

Y1 - 2015/1/1

N2 - A 62-year-old Filipino man with a history of chronic obstructive pulmonary disease, hypertension, and hyperlipidemia was admitted to the emergency department at Hospital A with recurrent fevers, weakness, and jaundice. The patient was evaluated and eventually discharged with a diagnosis of possible drug-induced hepatitis. One month later, the patient was admitted to Hospital B for recurrent fevers and weakness. The patient's hemoglobin was 3.8 g/dL. Six units of packed red blood cells (RBCs) were ordered for transfusion. The patient's sample typed as group B, D+, and the antibody screen was negative. All six units of packed RBCs appeared compatible (at immediate spin) and were transfused to the patient. His hemoglobin level 4 days post-transfusion was 9.3 g/dL, and the patient was discharged. The patient returned after a week for follow-up and his hemoglobin was found to have dropped to 8.5 g/dL, which continued to fall until it reached 7.0 g/dL. Additional packed RBCs were ordered for transfusion. During subsequent pre-transfusion compatibility testing, the antibody screen was found to be positive (all screening cells reactive at the antihuman globulin phase). An antibody identification panel was performed. The patient's serum was found to react with all panel cells tested, including the autocontrol tube. A direct antiglobulin test revealed the presence of both anti-IgG and anti-C3 coating the patient's RBCs. The specimen was then sent to a reference laboratory for further testing. Results from the reference lab testing revealed the presence of anti-Jk3 in the patient's serum. The patient was placed on steroids, and his reticulocyte count increased with no further signs of extravascular hemolysis. No additional transfusions were necessary. He was eventually discharged with a hemoglobin of 13.6 g/dL. The purpose of this case study is to report the findings of an extremely rare but clinically significant antibody, anti-Jk3.

AB - A 62-year-old Filipino man with a history of chronic obstructive pulmonary disease, hypertension, and hyperlipidemia was admitted to the emergency department at Hospital A with recurrent fevers, weakness, and jaundice. The patient was evaluated and eventually discharged with a diagnosis of possible drug-induced hepatitis. One month later, the patient was admitted to Hospital B for recurrent fevers and weakness. The patient's hemoglobin was 3.8 g/dL. Six units of packed red blood cells (RBCs) were ordered for transfusion. The patient's sample typed as group B, D+, and the antibody screen was negative. All six units of packed RBCs appeared compatible (at immediate spin) and were transfused to the patient. His hemoglobin level 4 days post-transfusion was 9.3 g/dL, and the patient was discharged. The patient returned after a week for follow-up and his hemoglobin was found to have dropped to 8.5 g/dL, which continued to fall until it reached 7.0 g/dL. Additional packed RBCs were ordered for transfusion. During subsequent pre-transfusion compatibility testing, the antibody screen was found to be positive (all screening cells reactive at the antihuman globulin phase). An antibody identification panel was performed. The patient's serum was found to react with all panel cells tested, including the autocontrol tube. A direct antiglobulin test revealed the presence of both anti-IgG and anti-C3 coating the patient's RBCs. The specimen was then sent to a reference laboratory for further testing. Results from the reference lab testing revealed the presence of anti-Jk3 in the patient's serum. The patient was placed on steroids, and his reticulocyte count increased with no further signs of extravascular hemolysis. No additional transfusions were necessary. He was eventually discharged with a hemoglobin of 13.6 g/dL. The purpose of this case study is to report the findings of an extremely rare but clinically significant antibody, anti-Jk3.

KW - ABL1

KW - AHG

KW - Abelson murine leukemia viral oncogene homolog 1

KW - Antihuman globulin

KW - BCR

KW - Breakpoint cluster region protein

KW - DAT

KW - DHTR

KW - Delayed hemolytic transfusion reaction

KW - Direct antiglobulin test

KW - IVIG

KW - Intravenous immunoglobulin

KW - JAK2

KW - Janus kinas 2 gene

KW - MRCP

KW - Magnetic resonance cholangiopancreatography

UR - http://www.scopus.com/inward/record.url?scp=84982975922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982975922&partnerID=8YFLogxK

M3 - Article

C2 - 26829178

AN - SCOPUS:84982975922

VL - 31

SP - 119

EP - 122

JO - Immunohematology / American Red Cross

JF - Immunohematology / American Red Cross

SN - 0894-203X

IS - 2

ER -